MONTREAL, QUÉBEC--(Marketwired - Feb. 23, 2017) - Knight Therapeutics Inc. (TSX:GUD) ("Knight") announced
today (i) the resignation of Ed Schutter and (ii) the appointment Dr. Sarit Assouline to Knight's Board of Directors. "I thank Ed
for his meaningful contributions to Knight since joining in early 2015," said Jonathan Ross Goodman, CEO of Knight. "In his
place, we welcome Dr. Sarit Assouline, a Hematologist at the Jewish General Hospital and associate professor of Medicine and
Oncology at McGill University, to our leadership team. Dr. Assouline is a well published clinician adding another level of
scientific diligence to Knight as we in-license innovative pharmaceuticals that touch the lives of patients."
About Dr. Sarit Assouline MD, MsC, FRCPC
Following her training in hematology and oncology at McGill University, Dr Assouline completed a Master's program in clinical
epidemiology and biostatistics at McGill University, and a CIHR funded drug development fellowship at the National Cancer
Institute of Canada Clinical Trials Group. Since 2005, she has been involved in the design and conduct of numerous clinical
trials testing novel therapies in patients with leukemia and lymphoma. These therapies include novel targeted monoclonal antibody
therapies, proteasome inhibitors, histone deacetylase inhibitors, and drugs targeting protein translation. Dr. Assouline is the
Director of the Chronic Myelogenous Leukemia Clinic of the Jewish General Hospital and, in this capacity, has contributed to
epidemiological research into the outcome of patients treated with tyrosine kinase inhibitors.
About Knight Therapeutics Inc.
Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or
in-licensing innovative pharmaceutical products for the Canadian and select international markets. Knight Therapeutics Inc.'s
shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web
site at www.gud-knight.com or www.sedar.com.
Forward-Looking Statement
This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward looking
statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially
from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these
forward-looking statements are based to be reasonable at the time they were prepared, but cautions the reader that these
assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may
ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current
expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form
for the year ended December 31, 2015. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any
forward-looking statements whether as a result of new information or future events, except as required by law.